Company Overview and News
Over my lifetime, I have invested in many different things. In the process of doing that, I have learned that there are really only two types of investors. As an investor, you are either active or passive. Being active implies directly managing or being in control of your investment. In contrast, as a passive investor, you allow others to manage the asset on your behalf. There are advantages and disadvantages to both approaches, and neither approach is necessarily better than the other.
Contactless Payment Transaction Market: Overview This report on the global contactless payment transaction market provides analysis for the period 2015–2025, wherein 2016 is the base year and the period from 2017 to 2025 is the forecast period. Data for 2015 has been included as historical information. The report covers market dynamics including drivers, restraints opportunities, and trends expected to influence the global contactless payment transaction market growth during the said period.
LONDON, UK / ACCESSWIRE / June 9, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Visa Inc. (NYSE: V). The Company announced on June 07, 2017, that it has signed 13 new partners to be a part of its Token Service Provider (TSP) program. The Company has executed this agreement under a step to accommodate the shift of payment industry from plastic to digital and to enable broader access to new standards, including tokenization.
In order to cash in on the growing trend of payments moving to the Internet of Things (IoT), Visa Inc. (V - Free Report) has signed 13 new partners to participate in its token service provider (TSP) program.
The report "Smart Ticketing Market by Product (Ticket Machine, E-Ticket, E-Kiosk), Component (Software and Hardware), System (Smart Card, Open Payment System, and Near-Field Communication), Application, and Geography - Global Forecast to 2022", published by MarketsandMarkets, The smart ticketing market is expected be valued at USD 10.22 Billion by 2022, growing at a CAGR of 7.93% between 2016 and 2022.
LONDON, Dec. 7, 2016 /PRNewswire/ -- The global near field communication (NFC) market is expected to reach USD 47.43 billion by 2024, according to a new report by Grand View Research, Inc. The industry is poised for an unprecedented growth over the forecast period owing to the increasing penetration of smartphones in the developing economy. Increasing adoption of mobile payment services has led to the intensive utilization of POS with the launch of e-wallet and Apple Watch.
"Growing security concerns for critical infrastructure and strict regulatory compliances are expected to drive the IoT security market" The Internet of Things (IoT) security market is projected to grow from USD 7.90 billion in 2016 to USD 36.95 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 36.1% due to rising concerns for security in critical infrastructures and strict security regulations imposed by regulating bodies.
Last year's Reflections From the Road write-up focused solely on Cloud Computing technology sectors (Big Data, M2M, and SaaS). The ensuing piece covers many road-trips, technologies, and company notes that I will cover in chronological order. For those readers who prefer company reports including fast-growing pre-IPO candidates - focus more on the ODDO Midcap Forum and Needham Growth Conference section.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...